Skip to content

Ketamine & Spravato

Fact-Checked and Approved by Dr. Saro Altinoglu Psy. D.

Ketamine and Spravato at Amend Malibu

Get fast-acting relief from treatment-resistant depression symptoms with Spravato (an FDA-approved esketamine nasal spray), to make more space for deep therapy work during your residential treatment at Amend in Malibu. This innovative psychedelic therapy stands at the forefront of our efforts to offer you add-on adjunctive therapies to help treat the complex challenges of Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD) with suicidal thoughts or ideation.

Relieve Depression Symptoms with Spravato in Malibu

Spravato nasal spray capitalizes on the unique properties of esketamine, presenting a groundbreaking approach to brain chemistry modulation, offering a glimmer of hope for those whose paths to recovery have been hindered by traditional therapies. This innovative treatment distinguishes itself through its mechanism of action, directly targeting NMDA receptors in the brain. This pathway is distinct from those affected by conventional antidepressants, enabling Spravato to provide rapid antidepressant effects and a noteworthy reduction in suicidal thoughts, serving as a crucial lifeline for clients in dire need.

In 2019, the FDA acknowledged the potential of Spravato to address the significant treatment gap in mental health care, approving its use for adults with treatment-resistant depression and for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior.

The efficacy of Spravato in swiftly mitigating symptoms of severe depression has been substantiated through rigorous clinical trials and studies. Some clientshave observed improvements in their condition as early as 24 hours after treatment, offering a significant advantage over traditional antidepressants and marking Spravato as a critical advancement in the fight against severe depression and suicidality.


What To Expect During a Spravato Treatment Session in Malibu

For each Spravato session, Amend transports clients less than 15-minutes down the Pacific Coast Highway to Plus by APN’s high-end healthcare clinic in Malibu. Here, clients can anticipate a structured and supportive environment tailored to maximize both comfort and treatment efficacy. Upon arrival, clients are settled in a quiet, comfortable space designed to foster a calm state of mind. The esketamine nasal spray is self-administered under the guidance of an experienced Plus by APN healthcare provider, ensuring the correct dosage and technique.

Following administration, clients sit back and relax under observation for at least two hours to monitor for potential side effects, such as dizziness, nausea, or elevated blood pressure, and to ensure their safety. This period also allows healthcare providers to assess the immediate effects of the treatment on the client’s symptoms. Clients are encouraged to relax, journal, doodle, or engage in quiet activities throughout the session.

The entire Spravato process is designed to be as smooth and reassuring as possible, providing a safe space for individuals to receive their treatment with the utmost care and professional oversight. Following the session, the Amend team transports each client back to residential care for integration back into treatment and their typical therapeutic schedules.


Tailored Spravato Treatment Experience

Spravato treatment at Amend is offered in partnership with Plus by APN Malibu and emphasizes individualized care, safety, and the overall well-being of our clients:

  • Supervised Administration: Spravato is administered in a controlled setting under the supervision of healthcare professionals at Plus by APN, ensuring client safety and monitoring for any adverse effects during and after treatment.
  • Comprehensive Care Strategy: Treatment with Spravato is typically part of a broader therapeutic strategy that includes oral antidepressants and integrative psychotherapy, providing a holistic approach to managing severe depression and suicidality.
  • Individualized Treatment Plans: Dosage and treatment schedules are customized based on each client’s unique needs and response to treatment, ensuring the most effective and compassionate care.


The Science on Spravato for Depression

The introduction of Spravato into clinical practice for mental health treatment is bolstered by a solid foundation of scientific research and clinical trials. Spravato’s impact extends beyond the rapid alleviation of depressive symptoms, contributing to lasting improvements in mental health:

  • Sustained Symptom Management: Studies indicate that the benefits of Spravato can extend for several weeks post-treatment, providing a stable foundation for recovery and rehabilitation from depression (Daly et al., 2019).
  • Quality of Life Enhancements: Clients treated with Spravato have reported significant improvements in their overall quality of life, daily functioning, and a reduction in suicidality, underscoring the profound effect of this treatment on aspects beyond mere symptom relief (Fu et al., 2020).
  • Renewed Hope: For individuals who have struggled with treatment resistant depression and medication-resistant depression, Spravato offers a new avenue for hope, potentially transforming the landscape of mental health treatment for those who felt their options were exhausted.
  • Demonstrated Efficacy in Treatment-Resistant Depression: Research by Daly et al. (2019) highlighted the significant reductions in depressive symptoms among TRD clients treated with Spravato compared to a placebo, showcasing its potential as a critical tool in the treatment arsenal against severe depression.
  • Rapid Reduction of Suicidal Ideation: Canuso et al. (2018) found that Spravato rapidly reduced suicidal thoughts in clients with Major Depressive Disorder, providing essential evidence of its life-saving potential with the alleviation of suicidal ideation (SI).


Navigating Spravato’s Side Effects and Treatment with Care

While Spravato is a powerful tool in treating severe depression, it does come with potential side effects and is not appropriate for everyone. Potential side effects include dissociation, dizziness, nausea, sedation, respiratory depression, and increased blood pressure. Spravato can increase the risk of suicidal thoughts and actions in some people. It also has the potential for misuse and abuse. For complete information on potential side effects, please visit Our Amend Treatment team and partners at Plus by APN are committed to providing the highest level of care, guiding clients through their treatment journey with empathy, expertise, and support.

Ketamine Treatment at Amend Malibu

Begin Your Recovery with Spravato at During Residential Treatment in Malibu

Incorporating Spravato into our holistic treatment philosophy, we at Plus by APN and Amend Treatment are dedicated to offering this innovative solution as part of a comprehensive plan tailored to your journey toward mental wellness.


Embark on a New Path

If you’re ready to explore how Spravato can be a part of your recovery, reach out for a confidential consultation today. Our compassionate team is here to support you every step of the way. Take your next step with a free, confidential consultation over the phone at (866) 875-3411, or submit your insurance information for a free benefits verification. Our experienced team looks forward to hearing your story and working with you to decide if we are the right fit.


Further Information and Support

Making informed decisions about your mental health treatment is vital. Our team and partners are available to provide detailed information about Spravato and how it integrates into a personalized residential treatment plan, ensuring you have the support you need on your journey to lasting wellness and recovery.


Contact Amend Treatment


Content References:

  • Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., … & Hough, D. (2018). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry, 175(7), 620-630.
  • Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., … & Drevets, W. C. (2019). Efficacy and safety of esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry, 76(2), 139-148.
  • Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., … & Van Nueten, L. (2019). Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). International Journal of Neuropsychopharmacology, 22(10), 616-630.
  • Fu, D. J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., … & Drevets, W. C. (2020). Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J Clin Psychiatry, 81(3), 19m13191.
  • FDA (2019). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. U.S. Food and Drug Administration.
Skip to content